Orchestra BioMed Holdings (OBIO) Gains from Investment Securities (2022 - 2023)
Orchestra BioMed Holdings (OBIO) posted quarterly Gains from Investment Securities of $294000.0 for Q1 2023, up 102.76% year-over-year from $145000.0 in Q1 2022, and up 30.09% quarter-over-quarter from $226000.0 in Q4 2022.
Powered by 
Analysis
Orchestra BioMed Holdings (OBIO) Gains from Investment Securities (2022 - 2023) Analysis & Trends
Orchestra BioMed Holdings (OBIO) has reported Gains from Investment Securities for 2 consecutive years, with $294000.0 the latest figure, recorded in Q1 2023.
- In Q1 2023, Gains from Investment Securities rose 102.76% year-over-year to $294000.0; the TTM figure through Dec 2023 stood at $294000.0 (down 78.22% YoY), while the FY2023 annual figure was $294000.0, down 78.22% from the prior year.
- Gains from Investment Securities climbed to $294000.0 in Q1 2023 per OBIO's latest filing, from $226000.0 in the prior quarter.
- Across five years, Gains from Investment Securities topped out at $1.0 million in Q2 2022 and bottomed at -$36000.0 in Q3 2022.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Orchestra BioMed Holdings | 322.25 Mn | 127.72 Mn | 63,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2023 | 294,000.00 |
| Dec 31, 2022 | 226,000.00 |
| Sep 30, 2022 | -36,000.00 |
| Jun 30, 2022 | 1.02 Mn |
| Mar 31, 2022 | 145,000.00 |